CU Boulder spinoff Muse Biotechnology raises $23M

BOULDER — Biotech startup Muse Biotechnology Inc. has raised $23 million in new equity Series B financing.

The funding was reported in a Regulation D filing with the U.S. Securities and Exchange Commission, Feb. 28, and was led by Venrock, a venture-capital firm based in Palo Alto, Calif., according to a company press release. Other investors included Foresite Capital and Paladin Capital, as well as Series A investors, NanoDimension and Spruce/MLS.
Muse Bio’s ForgeCraft technology allows for precision editing of the human genome.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!